... to reducing the morbidity associated with current therapeutic strategies, especially lymph node dissection. This study aimed to determine whether the laterality of the dominant intraprostatic lesion correlates with the laterality of pelvic lymph node involvement in patients with node-positive prostate cancer...

...Banchao Shen; Fuli Wang Background: Lymph node (LN) staging remains critical for risk stratification and treatment selection in intermediate-risk prostate cancer (IR-PCa). Conventional imaging modalities have limited sensitivity, and extended pelvic LN dissection (ePLND) is associated...

...Mohamad Hatem Albarghouth; Mirjam Leeder; Katharina Leucht; Philipp Seifert; Martin Freesmeyer; Oliver W. Hakenberg; Marc-Oliver Grimm Introduction: Accurate preoperative nodal staging is crucial for treatment planning in prostate cancer (PCa). Extended pelvic lymph node dissection (ePLND...

...Niklas Behnel; Lucas Engelage; Agron Lumiani; Alexander Buchner; Leo Federico Stadelmeier; Ronald Sroka; Alexander Tamalunas Introduction: Transition zone PSA density (TZ-PSAD) was proposed to improve prostate cancer detection by normalizing PSA to the compartment most affected by benign prostatic...

...Martin Schostak; Emma Peklo; Inga Peters; Stefan Machtens; Heinz-Peter Schlemmer; Christian Thomas; Angelika Borkowetz Introduction: Focal therapy (FT) represents a minimally invasive option for selected patients with localized prostate cancer (PCa), aiming to achieve oncological control while...

... the harms and oncological benefits of pelvic lymph node dissection (PLND) during radical prostatectomy (RP) in prostate cancer patients at risk for regional lymph node invasion. Methods: Patients with cN0M0 prostate cancer who underwent RP between January 2013 and February 2023 were included. Patients were...

... advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2025 Prostate cancer Robotic-assisted...

... Introduction: Extended pelvic lymphadenectomy (ePLND) is the gold standard for staging prostate cancer (PCa) in patients at risk of lymph node invasion, though its oncological benefit remains debated. Indocyanine green-guided PLND (ICG-PLND) has emerged as a less morbid alternative, but its long-term...

... conditions and treatment options. In prostate cancer, complex medical terminology can hamper comprehension and informed decision-making. This study evaluates the readability of prostate cancer PEMs to determine if they meet recommended standards for lay audiences. Methods: A selection of standardized...

...Hua Luo; Gaoyuan Liao; Yanghan Liu Introduction: This comprehensive review and meta-analysis investigates the effectiveness of neoadjuvant hormone therapy (NHT) in conjunction with radical prostatectomy (RP) for patients diagnosed with clinical stage T3 (cT3) prostate cancer (PCa) patients. Our...

...Christos Philippou; Simon Gloger; Burkhard Ubrig; Norman Bitterlich; Emilia Krassimirova Naseva; Hans-Joerg Sommerfeld; Andreas Wiedemann; Dirk Theegarten; Haji Abdulla; Stathis Philippou Introduction: Osseous metastasis is the most common site of distant spread in prostate cancer. Several factors...

...Moustafa Elleisy; Irene Resch; Ozan Yurdakul; Nicolai A. Hübner; Shahrokh Shariat Introduction: Abiraterone acetate is an inhibitor of androgen biosynthesis and is approved as a treatment for metastatic castration-resistant and metastatic castration-sensitive prostate cancer. Neither relugolix nor...

...Teresa Pina-Vaz; Alberto Costa Silva; Gabriel Costa; Micael Gonçalves; Angela Fernandes; Frederico Carmo Reis; Pedro Nobre; Carmen Lisboa; Acacio Rodrigues; João Alturas-Silva; Carlos Martins-Silva Introduction: Chronic inflammation and infections have been implicated in prostate cancer (PCa...

... or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2025 Prostate cancer Androgen receptor Prostate-specific antigen Androgen receptor signaling inhibitors (ARSIs) have been used as novel regimens with standard androgen...

...-free survival (PFS) after urological cancers. Results: A total of 20 studies were eligible. Three studies were on bladder cancer, four on prostate cancer, seven on renal cell carcinoma (RCC), and six on urothelial cancers. Meta-analysis showed that low GNRI was a statistically significant predictor...

... prior prostatic intervention. Bladder cancer Prostate cancer Radical cystectomy Prostate cancer is the commonest non-cutaneous malignancy in men and is managed in the early stages with radical prostatectomy or radiation therapy [ 1 ]. Accordingly, the management of persisting obstructive...

... evaluated. The study focused on patients after radical prostatectomy (RP) for prostate cancer (PCa), radical cystectomy (RC) for bladder cancer (BCa), or (partial) nephrectomy for kidney cancer (KC). Results: Overall, 9,039 patients (6,898 (76.3%) after RP, 1,427 (15.8%) after RC, 714 (7.9%) after (partial...

... study in patients with locally advanced and metastatic hormone-sensitive prostate cancer (PC). This analysis explores the efficacy and safety of leuprorelin in patients with PC and an indication for androgen deprivation therapy (ADT) in routine practice. Methods: Safety assessment focused...

... in a delay in diagnosis and treatment of prostate cancer (PC). Methods: A monocentric, retrospective analysis was conducted at a university cancer center. Included were all patients with untreated PC diagnosed between January 2019 and December 2021. The observation covered 22 months of the SARS-CoV-2...

...Maximilian Oberneder; Thomas Henzler; Martin Kriegmair; Tibor Vag; Matthias Roethke; Sabine Siegert; Roland Lang; Julia Lenk; Joshua Gawlitza Introduction: Multiparametric MRI (mpMRI) is gold standard for the primary diagnostic work-up of clinically significant prostate cancer (csPCa). The aim...